![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
FJ White and RY Wang
Extracellular single-cell recording and microiontophoretic techniques were used to characterize the presynaptic dopamine (DA) receptors (autoreceptors) on A10 DA neurons in the rat ventral tegmental area. Thus, the ability of various agonists to inhibit the activity of A10 DA neurons was compared. DA and the DA agonists N-n-propylnorapomorphine (NPA), apomorphine, lisuride, pergolide, LY141865 and bromocriptine all suppressed the activity of A10DA neurons. NPA was the most potent exogenous agonist, exerting effects that were similar to an equimolar concentration of DA (0.01 M). When ejected at equimolar concentrations (0.01 M) and equivalent ejection currents, the rank order of potency for these agonists was DA = NPA greater than LY141865 greater than pergolide = lisuride = apomorphine greater than norepinephrine greater than bromocriptine. The alpha-2 adrenoceptor agonist clonidine, the beta adrenoceptor agonist isoproterenol, the D-1 specific DA agonist SKF 38393 and the hallucinogenic ergot lysergic acid diethylamide exerted only weak effects or were inactive. The D-2 specific DA antagonist sulpiride completely blocked the rate-suppressant effects of DA and DA agonists but not those of gamma-aminobutyric acid. The purported D-1 specific DA antagonist SCH 23390 failed to block the effects of either DA or the D-2 specific DA agonist LY141865. These results indicate that DA agonists suppress the activity of the majority of A10 DA neurons by acting directly on somatodendritic DA autoreceptors which exhibit the pharmacological characteristics of D-2 receptors.
This article has been cited by other articles:
|
|
 |
|
  J. D. Kilts, H. S. Connery, E. G. Arrington, M. M. Lewis, C. P. Lawler, G. S. Oxford, K. L. O'Malley, R. D. Todd, B. L. Blake, D. E. Nichols, et al. Functional Selectivity of Dopamine Receptor Agonists. II. Actions of Dihydrexidine in D2L Receptor-Transfected MN9D Cells and Pituitary Lactotrophs J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Linnér, H. Endersz, D. Öhman, F. Bengtsson, M. Schalling, and T. H. Svensson Reboxetine Modulates the Firing Pattern of Dopamine Cells in the Ventral Tegmental Area and Selectively Increases Dopamine Availability in the Prefrontal Cortex J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 540 - 546. [Abstract] [Full Text]
|
|
|
|
|
|
E. B. Bunney, S. B. Appel, and M. S. Brodie Electrophysiological Effects of Cocaethylene, Cocaine, and Ethanol on Dopaminergic Neurons of the Ventral Tegmental Area J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 696 - 703. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Marinelli and F. J. White Enhanced Vulnerability to Cocaine Self-Administration Is Associated with Elevated Impulse Activity of Midbrain Dopamine Neurons J. Neurosci., December 1, 2000; 20(23): 8876 - 8885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, R. Xu, T. Sasaoka, S. Tonegawa, M.-P. Kung, and E.-B. Sankoorikal Dopamine D2 Long Receptor-Deficient Mice Display Alterations in Striatum-Dependent Functions J. Neurosci., November 15, 2000; 20(22): 8305 - 8314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Di Giovanni, M. Di Mascio, V. Di Matteo, and E. Esposito Effects of Acute and Repeated Administration of Amisulpride, a Dopamine D2/D3 Receptor Antagonist, on the Electrical Activity of Midbrain Dopaminergic Neurons J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 51 - 57. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
